Treatment of hemophilia B: Focus on recombinant factor IX

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 33-38

  Franchini, Massimo ^a   Frattini, Francesco ^a   Crestani, Silvia ^a   Sissa, Cinzia ^a   Bonfanti, Carlo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

Bleeding; Blood clotting disorder; On demand treatment; Plasma derived fix concentrate; Prophylaxis treatment; Recombinant FIX products

Indexed keywords

ALBUMIN; ALPHANINE SD; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING INHIBITOR; HAEOMINE; IMMUNOGLOBULIN G; MACROGOL; MONOINE; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HUMAN; INDIVIDUALIZATION; NONHUMAN; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT PLANNING;

EID: 84873896239     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S31582     Document Type: Review

References (55)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003; 361(9371):1801-1809.
2. Mannucci PM, Tuddenham EG. The hemophilias: from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
3. Kurachi K, Kurachi S, Furukawa M, Yao SN. Biology of factor IX. Blood Coagul Fibrinolysis. 1993;4(6):953-973.
4. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992;326(12):800-806.
5. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82(2):165-174.
6. Oldenburg J, Schwaab R. Molecular biology of blood coagulation. Semin Thromb Hemost. 2001;27(4):313-324.
7. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
8. Makris M. Is VIII worse than IX? Blood. 2009;114(4):750-751.
9. Lowe GD, Ludlam CA. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost. 2008;6(11):1982-1983.
10. Tagariello G, Iorio A, Santagostino E, et al; Italian Association Hemophilia Centre. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood. 2009;114(4):779-784.
11. Franchini M, Frattini F, Crestani S, Bonfanti C. Haemophilia B: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2012;13(14):2053-2063.
12. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008;14(Suppl 3):10-18.
13. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost. 2011;106(3):398-404.
14. Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost. 2003;1(7):1349-1355.
15. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25-32.
16. Azzi A, Ciappi S, Zakvrewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated, factor VIII concentrates. Am J Hematol. 1992;39(3):228-230.
17. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012;52(7):1482-1489.
18. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010;16(2):296-304.
19. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol. 2006;132(1):13-24.
20. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982;79(21):6461-6464.
21. Choo KH, Gould KG, Rees DJ, Brownlee GG. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature. 1982; 299(5879):178-180.
22. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008; 99(5):840-850.
23. Aznar JA, Lucía F, Abad-Franch L, et al. Haemophilia in Spain. Haemophilia. 2009;15(3):665-675.
24. Monahan PE, Di Paola J. Recombinant factor IX for clinical and research use. Semin Thromb Hemost. 2010;36(5):498-509.
25. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost. 2002;87(3):431-435.
26. Ewenstein BM, Joist JH, Shapiro AD, et al; Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002;42(2):190-197.
27. Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005; 105(2):518-525.
28. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011;17(2):179-184.
29. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.
30. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7(2):133-139.
31. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia. 2007;13(1):2-8.
32. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001; 98(13):3600-3606.
33. Berntorp E, Keeling D, Makris M, et al. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. Haemophilia. 2012;18(4):503-509.
34. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78(1):261-265.
35. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol. 2011;72(4):553-562.
36. Astermark J, Santagostino E, Keith Hoots W. Clinical issues in inhibitors. Haemophilia. 2010;16(Suppl 5):54-60.
37. Franchini M, Lippi G, Montagnana M, et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis. 2009;20(4):225-229.
38. Kisker CT, Eisberg A, Schwartz B; Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia. 2003;9(3):279-284.
39. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13(3):233-243.
40. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 2010;16(3):460-468.
41. Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia. 2011;17(3):494-499.
42. Ivens IA, Baumann A, McDonald TA, Humphries T, Michaels LA, Mathew P. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19(1):11-20.
43. Elm T, Ostergaard H, Tranholm M. Dose response and prolonged effect of 40K PEG-FIX on bleeding in hemophilia B mice [abstract]. J Thromb Haemost. 2009;7(Suppl 2):OC-MO-084.
44. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011; 118(10):2695-2701.
45. Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. Epub September 23, 2012.
46. Valentino LA. Recombinant FIXFc: a novel therapy for the royal disease? Expert Opin Biol Ther. 2011;11(10):1361-1368.
47. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
48. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-672.
49. Biogen Idec. Study of recombinant factor IX Fc fusion protein (rFIXFc) in subjects with hemophilia B. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated October 11, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01027364. NLM identifier: NCT01027364. Accessed December 18, 2012.
50. Biogen Idec. Long-term safety and efficacy of recombinant human coagulation factor IX fusion protein (rFIXFc) in the prevention and treatment of bleeding episodes in previously treated subjects with hemophilia B. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated July 12, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01425723. NLM identifier: NCT01425723. Accessed December 18, 2012.
51. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(4):634-644.
52. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rFIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405-2411.
53. CSL Behring. A safety and efficacy study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated November 28, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01496274. NLM identifier: NCT01496274. Accessed January 30, 2013.
54. Gomperts ED, Lee M, Nichols T, Griffith M. IB1001, a new recombinant factor IX preparation: initial safety and characterization [abstract]. J Thromb Haemost. 2009; Volume 7, Supplement 2: Abstract OC-MO-086.
55. Martinowitz U, Shapiro A, Quon DV, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012;18(6):881-887.